Abstract
Extracellular matrix metalloproteinases (MMPs) are a family of zinc-dependent neutral endopeptidases involved in physiological and pathological processes, through the cleavage of extracellular matrix. MMPs are capable of degrading essentially all matrix components, which is crucial for malignant tumor growth, invasion, metastasis and angiogenesis. The vertebrates MMP family includes at least 26 enzymes (23 have been known in humans) with only MMP-1, 2, and 7 experimentally validated as targets for antitumoral drug design. However, inhibition of MMP-1 has been hypothesized to be the cause of the clinically observed musculoskeletal syndrome when broad spectrum inhibitors are used. On the other hand, MMP-9 is a tricky enzyme, since its inhibition might be useful in treating patients with early-stage cancers, but MMP-9 is an anti-target in patients with advanced disease. So, MMP-9 inhibition should also be prevented. Therefore, selective MMP-2 inhibition arises as a pursued profile for MMP binders. Among them, hydroxamates have been extensively studied as small molecule drug candidates characterized by an effective zinc-binding group plus additional side chains responsible for the selectivity. This article pays particular attention to MMP-2 selectivity on hydroxamate-type inhibitors, especially against MMP-9, and their chemical structure, SAR, general synthetic methods, and molecular modelling studies are here reviewed in order to inspire further design of new effective anticancer agents.
Keywords: Hydroxamate, selective matrix metalloproteinase-2 inhibitors, synthesis, molecular modelling, matrix metalloproteinases, endopeptidases, malignant tumor growth, invasion, metastasis, angiogenesis
Current Medicinal Chemistry
Title: MMP-2 Selectivity in Hydroxamate-Type Inhibitors
Volume: 19 Issue: 7
Author(s): P. Serra, M. Bruczko, J. M. Zapico, A. Puckowska, M. A. Garcia, S. Martin-Santamaria, A. Ramos and B. de Pascual-Teresa
Affiliation:
Keywords: Hydroxamate, selective matrix metalloproteinase-2 inhibitors, synthesis, molecular modelling, matrix metalloproteinases, endopeptidases, malignant tumor growth, invasion, metastasis, angiogenesis
Abstract: Extracellular matrix metalloproteinases (MMPs) are a family of zinc-dependent neutral endopeptidases involved in physiological and pathological processes, through the cleavage of extracellular matrix. MMPs are capable of degrading essentially all matrix components, which is crucial for malignant tumor growth, invasion, metastasis and angiogenesis. The vertebrates MMP family includes at least 26 enzymes (23 have been known in humans) with only MMP-1, 2, and 7 experimentally validated as targets for antitumoral drug design. However, inhibition of MMP-1 has been hypothesized to be the cause of the clinically observed musculoskeletal syndrome when broad spectrum inhibitors are used. On the other hand, MMP-9 is a tricky enzyme, since its inhibition might be useful in treating patients with early-stage cancers, but MMP-9 is an anti-target in patients with advanced disease. So, MMP-9 inhibition should also be prevented. Therefore, selective MMP-2 inhibition arises as a pursued profile for MMP binders. Among them, hydroxamates have been extensively studied as small molecule drug candidates characterized by an effective zinc-binding group plus additional side chains responsible for the selectivity. This article pays particular attention to MMP-2 selectivity on hydroxamate-type inhibitors, especially against MMP-9, and their chemical structure, SAR, general synthetic methods, and molecular modelling studies are here reviewed in order to inspire further design of new effective anticancer agents.
Export Options
About this article
Cite this article as:
Serra P., Bruczko M., M. Zapico J., Puckowska A., A. Garcia M., Martin-Santamaria S., Ramos A. and de Pascual-Teresa B., MMP-2 Selectivity in Hydroxamate-Type Inhibitors, Current Medicinal Chemistry 2012; 19 (7) . https://dx.doi.org/10.2174/092986712799320628
DOI https://dx.doi.org/10.2174/092986712799320628 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Red Wine, Arterial Stiffness and Central Hemodynamics
Current Pharmaceutical Design Intravitreal Bevacizumab (Avastin®) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture
Current Diabetes Reviews Intraventricular Recombinant Tissue Plasminogen Activator in Treatment of Aneurysmal Intraventricular Hemorrhage: A Meta-Analysis
Current Drug Targets A More Accurate Approach to Molecular Genetics Analysis in Vascular Disease
Cardiovascular & Hematological Disorders-Drug Targets The Role of T and B Cells in Atherosclerosis: Potential Clinical Implications
Current Pharmaceutical Design Immunophilins and Cardiovascular Complications
Current Medicinal Chemistry Hypoperfusion of the Aortic Wall Secondary to Degeneration of Adventitial Vasa Vasorum Causes Abdominal Aortic Aneurysms
Current Drug Targets Prosthetic Valve Endocarditis: Diagnostic Approach and Treatment Options
Cardiovascular & Hematological Disorders-Drug Targets Atherosclerosis as an Inflammatory Disease
Current Pharmaceutical Design Therapeutic Applications of Prostaglandins and Thromboxane A2 Inhibitors in Abdominal Aortic Aneurysms
Current Drug Targets Management of Blood Pressure and Heart Rate in Patients with Acute Stroke
Current Pharmaceutical Design Nanomedicine for Gene Delivery for the Treatment of Cardiovascular Diseases
Current Gene Therapy Toll-Like Receptor 4 Signaling Pathway as a Potential Targets for Stroke-Induced Inflammation
Current Signal Transduction Therapy Immune-Mediated Mechanisms in Atherosclerosis: Prevention and Treatment of Clinical Manifestations
Current Pharmaceutical Design Development of Nucleic Acid Drugs for Neurological Disorders
Current Topics in Medicinal Chemistry Therapeutic Strategies to Correct Proteostasis-Imbalance in Chronic Obstructive Lung Diseases
Current Molecular Medicine Mast Cells: Pivotal Players in Cardiovascular Diseases
Current Cardiology Reviews Inflammation-Induced Thrombosis: Mechanisms, Disease Associations and Management
Current Pharmaceutical Design A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry